Abbott stock posts modest gain amid fragile momentum below MA-20 resistance: weekly review

Traders Union
All News
Financial News
Abbott Laboratories up 3.10% this week

Highlights

Abbott trades well below key moving averages, signaling persistent bearish momentum in medium- and long-term trends.
Technical indicators show overwhelming selling pressure, with the stock deeply oversold despite a recent short-term rebound.
Expected price action ranges from $83.70 to $90.70 next week, with upside breakout unlikely and downside risk prevailing.

Upbeat earnings and guidance boost sentiment as diabetes segment outperforms

Abbott reported higher first-quarter 2026 earnings, led by strong growth in its diabetes care segment and increased adoption of FreeStyle Libre glucose monitoring systems. The company raised its full-year 2026 guidance and maintained its shareholder returns strategy, highlighted by the most recent $0.63 per share quarterly dividend paid in mid-May 2026. Institutional investors made notable adjustments to their shareholdings during the fourth quarter, while Abbott continued to prioritize research and development, selective acquisitions, and regular dividends alongside managing industry challenges.

Dominant seller momentum and oversold signals weigh on weekly setup

On the weekly timeframe, all major indicators remain bearish. ABT is decisively below the MA-20 ($105.87), MA-50 ($120.53), and MA-200 ($113.00), with the MA-20 serving as the closest resistance level. Momentum indicators, including MACD and ADX, signal ongoing seller control, while oscillators such as RSI (18.33), Stochastic RSI, and CCI indicate the stock is in deeply oversold territory. Weekly volatility stands at 4.09%, and Bull/Bear Power confirms sellers dominate. ABT sits near weekly resistance, with strong overhead barriers and fragile recovery momentum.

Sideways bias with limited upside as indicators reinforce downward risks

Forecast for the next five trading days suggests ABT will likely trade sideways within the $83.70 to $90.70 range, reflecting persistent medium- and long-term weakness on weekly indicators. The probability of a sustained upward move is low, given bearish readings across RSI, ADX, MACD, and CCI. Should ABT break above $90.70, a short-term rally could ensue, but the bias favors a retest of support — a close below $83.70 would reinforce the downtrend and may prompt renewed selling pressure.

Jainam Mehta, market strategist, sees Abbott holding above $87.00 this week but notes persistent bearish momentum despite the fundamental strength from improved guidance and strong diabetes segment growth. Technical indicators remain deeply negative, with ABT pinned below its major moving averages and all signals, from RSI to MACD, confirming ongoing seller dominance. The analyst believes a sideways move within the $83.70 to $90.70 band is most probable, with a potential breakdown if support fails. "Until ABT can reclaim levels above the $90.70 resistance, I view any bounce as fragile — I’m watching for a possible retest of support before considering directional trades this week."

Earlier, analysts noted that Abbott Laboratories was experiencing persistent bearish momentum as ongoing technical weakness outweighed pockets of fundamental strength. The current analysis reinforces this outlook, highlighting continued downside risks and suggesting that traders should closely monitor for any sustained move above $90.70, which could indicate an early shift in the prevailing trend.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.